Orphazyme CEO on sale: "It’s sad, but we tried everything"

Anders Vadsholt, CEO of Orphazyme, says every possible avenue to save the company was explored, but on Tuesday, Orphazyme was bought by Kempharm.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

A small sum of money, a legal suit, and a shadow on the stock market.

This is all that’s left after the company’s creditors approved a restructuring plan at an in-court meeting on Monday at the Danish Maritime and Commercial High Court, which cleared the way forward to selling Orphazyme’s activities to US-based Kempharm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs